市場調査レポート

商品コード

1309041

遺伝学的検査市場：疾患タイプ、技術、用途、エンドユーザー別-2023-2030年の世界予測

Hereditary Testing Market by Disease Type, Technology, Application, End-User - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030

出版日: 2023年06月12日 | 発行: 360iResearch

| ページ情報: 英文 186 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

PDF, Excel & Online Access - 1 Year (Single User License)

USD 4,749 739,704円

レポートPDF及びExcelを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。購入後1年間、レポートにオンラインでアクセス可能です。

PDF, Excel & Online Access - 1 Year (Up to 5 User License)

USD 5,749 895,464円

レポートPDF及びExcelを5名まで共有ご利用頂けるライセンスです。ご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。購入後1年間、レポートにオンラインでアクセス可能です。

PDF, Excel & Online Access - 1 Year (Site License)

USD 6,749 1,051,224円

レポートPDF及びExcelを同一事業所（所在地）内のすべての方でご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。購入後1年間、レポートにオンラインでアクセス可能です。

PDF, Excel & Online Access - 1 Year (Enterprise User License)

USD 8,749 1,362,744円

レポートPDF及びExcelを同一企業の全世界の方にご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。購入後1年間、レポートにオンラインでアクセス可能です。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=155.76円

ご注意事項 :

本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

遺伝学的検査の世界市場は、2023年に51億5,517万米ドル、CAGR 8.15%で大幅な成長が予測され、2030年には89億3,475万米ドルという驚異的な規模に達する見込みです。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは世界の遺伝学的検査市場を評価するために不可欠です。事業戦略と製品満足度の主要指標を調査することで、ベンダーの包括的な評価を提供し、ユーザーは特定のニーズに基づいた情報をもとに意思決定を行うことができます。この高度な分析により、ベンダーは成功の度合いが異なる4つの象限に整理されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析では、特定の市場領域におけるベンダーの現状を洞察することができます。全体的な収益、顧客基盤、その他の主要指標に対するベンダーの貢献度を比較することで、企業が市場シェアを争う際に、自社の業績や直面している状況をより深く理解することができます。また、本分析では、調査した基準年において、特定のセクターがどの程度競合しているのか、蓄積、断片化の優位性、合併の特徴についても明らかにしています。

本レポートは、以下のポイントに関する洞察を提供します：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提供します。

2.市場の発展：有利な新興市場に関する詳細情報を提供し、市場の成熟セグメントにおける浸透度を分析します。

3.市場の多様化：新製品の上市、未開発地域、最近の開発、投資に関する詳細情報を提供します。

4.市場の動向：COVID-19、ロシア・ウクライナ紛争、高インフレの累積的な影響を包括的に理解することができます。

5.競合の評価と情報：主要企業の市場シェア、戦略、製品、認証、規制状況、特許状況、製造能力を網羅的に評価します。

6.製品開発およびイノベーション：将来技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような質問にお答えします：

1.遺伝学的検査の世界市場規模および予測は？

2.予測期間中、世界の遺伝学的検査市場を形成するCOVID-19の阻害要因と影響は？

3.遺伝学的検査の世界市場において予測期間中に投資すべき製品/セグメント/アプリケーション/分野は？

4.遺伝学的検査の世界市場における競争戦略は？

5.遺伝学的検査の世界市場における技術動向と規制の枠組みは？

6.遺伝学的検査の世界市場における主要ベンダーの市場シェアは？

7.遺伝学的検査の世界市場への参入には、どのような形態や戦略的な動きが適していると考えられるか？

市場力学
- 促進要因
  - 潜在的な病気の根本原因を見つけるためのDNAの変化や変異の探索
  - 妊婦別検査の増加
  - 高度なゲノム配列決定に関する研究開発活動の高まり
- 抑制要因
  - 限定的な払い戻しポリシー
- 機会
  - 共同商品開発
  - バリューチェーン内での魅力的な投資と合併活動
- 課題
  - 遺伝学的検査の不確実な結果
市場動向
COVID-19の累積的な影響
ロシア・ウクライナ紛争の累積的影響
高インフレの累積的影響
ポーターのファイブフォース分析
バリューチェーンとクリティカルパス分析
規制の枠組み
顧客のカスタマイズ

第6章遺伝学的検査市場：疾患タイプ別

遺伝性がん検査
- 乳がん
- 子宮頸がん
- 結腸直腸がん
- 肺がん
- 黒色腫
- 卵巣がん
- 膵臓がん
- 前立腺がん
- 肉腫
- 胃がんまたは胃がん
- 子宮がん
遺伝性非がん検査
- 遺伝子検査
  - 心臓病
  - 希少疾患
新生児遺伝子スクリーニング
非侵襲的な出生前検査と保因者スクリーニング検査
着床前遺伝子診断とスクリーニング

第7章遺伝学的検査市場：技術別

生化学
細胞遺伝学
分子検査

第8章遺伝学的検査市場：用途別

がんの診断
心血管疾患の診断
遺伝病の診断

第9章遺伝学的検査市場：エンドユーザー別

クリニック
病院

第10章南北アメリカの遺伝学的検査市場

アルゼンチン
ブラジル
カナダ
メキシコ
米国

第11章アジア太平洋地域の遺伝学的検査市場

オーストラリア
中国
インド
インドネシア
日本
マレーシア
フィリピン
シンガポール
韓国
台湾
タイ
ベトナム

第12章欧州・中東・アフリカの遺伝学的検査市場

デンマーク
エジプト
フィンランド
フランス
ドイツ
イスラエル
イタリア
オランダ
ナイジェリア
ノルウェー
ポーランド
カタール
ロシア
サウジアラビア
南アフリカ
スペイン
スウェーデン
スイス
トルコ
アラブ首長国連邦
英国

第13章競合情勢

FPNVポジショニングマトリクス
市場シェア分析：主要企業別
競合シナリオ分析：主要企業別

第14章掲載企業一覧

第15章付録

ディスカッションガイド
ライセンスと価格について

図表

LIST OF FIGURES

FIGURE 1. HEREDITARY TESTING MARKET RESEARCH PROCESS
FIGURE 2. HEREDITARY TESTING MARKET SIZE, 2022 VS 2030
FIGURE 3. HEREDITARY TESTING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2022 VS 2030 (%)
FIGURE 5. HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2022 VS 2030 (%)
FIGURE 6. HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2022 VS 2030 (%)
FIGURE 7. HEREDITARY TESTING MARKET SIZE, BY END-USER, 2022 VS 2030 (%)
FIGURE 8. HEREDITARY TESTING MARKET SIZE, BY REGION, 2022 VS 2030 (%)
FIGURE 9. HEREDITARY TESTING MARKET DYNAMICS
FIGURE 10. HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 11. HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 12. HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 13. HEREDITARY TESTING MARKET SIZE, BY END-USER, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 14. AMERICAS HEREDITARY TESTING MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES HEREDITARY TESTING MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 16. ASIA-PACIFIC HEREDITARY TESTING MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA HEREDITARY TESTING MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 18. HEREDITARY TESTING MARKET, FPNV POSITIONING MATRIX, 2022
FIGURE 19. HEREDITARY TESTING MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

TABLE 1. HEREDITARY TESTING MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
TABLE 3. HEREDITARY TESTING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 5. HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 6. HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. HEREDITARY TESTING MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. HEREDITARY TESTING MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. HEREDITARY TESTING MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. HEREDITARY TESTING MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. HEREDITARY TESTING MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. HEREDITARY TESTING MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. HEREDITARY TESTING MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. HEREDITARY TESTING MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. HEREDITARY TESTING MARKET SIZE, BY SARCOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. HEREDITARY TESTING MARKET SIZE, BY STOMACH OR GASTRIC CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. HEREDITARY TESTING MARKET SIZE, BY UTERINE CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 19. HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 21. HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. HEREDITARY TESTING MARKET SIZE, BY CARDIAC DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. HEREDITARY TESTING MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. HEREDITARY TESTING MARKET SIZE, BY NEWBORN GENETIC SCREENING, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. HEREDITARY TESTING MARKET SIZE, BY NON-INVASIVE PRENATAL TESTING & CARRIER SCREENING TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. HEREDITARY TESTING MARKET SIZE, BY PREIMPLANTATION GENETIC DIAGNOSIS & SCREENING, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 28. HEREDITARY TESTING MARKET SIZE, BY BIOCHEMICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. HEREDITARY TESTING MARKET SIZE, BY CYTOGENETIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. HEREDITARY TESTING MARKET SIZE, BY MOLECULAR TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 32. HEREDITARY TESTING MARKET SIZE, BY CANCER DIAGNOSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. HEREDITARY TESTING MARKET SIZE, BY CARDIOVASCULAR DISEASE DIAGNOSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. HEREDITARY TESTING MARKET SIZE, BY GENETIC DISEASE DIAGNOSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 36. HEREDITARY TESTING MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. HEREDITARY TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS HEREDITARY TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 46. ARGENTINA HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 47. ARGENTINA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 48. ARGENTINA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 49. ARGENTINA HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 50. ARGENTINA HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 51. ARGENTINA HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 52. ARGENTINA HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 53. BRAZIL HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 54. BRAZIL HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 55. BRAZIL HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 56. BRAZIL HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 57. BRAZIL HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 58. BRAZIL HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 59. BRAZIL HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 60. CANADA HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 61. CANADA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 62. CANADA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 63. CANADA HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 64. CANADA HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 65. CANADA HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 66. CANADA HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 67. MEXICO HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 68. MEXICO HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 69. MEXICO HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 70. MEXICO HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 71. MEXICO HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 72. MEXICO HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 73. MEXICO HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES HEREDITARY TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 81. UNITED STATES HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 82. ASIA-PACIFIC HEREDITARY TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 83. ASIA-PACIFIC HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 84. ASIA-PACIFIC HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 85. ASIA-PACIFIC HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 86. ASIA-PACIFIC HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 87. ASIA-PACIFIC HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 88. ASIA-PACIFIC HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 89. ASIA-PACIFIC HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 90. AUSTRALIA HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 91. AUSTRALIA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 92. AUSTRALIA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 93. AUSTRALIA HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 94. AUSTRALIA HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 95. AUSTRALIA HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 96. AUSTRALIA HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 97. CHINA HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 98. CHINA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 99. CHINA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 100. CHINA HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 101. CHINA HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 102. CHINA HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 103. CHINA HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 104. INDIA HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 105. INDIA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 106. INDIA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 107. INDIA HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 108. INDIA HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 109. INDIA HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 110. INDIA HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 111. INDONESIA HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 112. INDONESIA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 113. INDONESIA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 114. INDONESIA HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 115. INDONESIA HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 116. INDONESIA HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 117. INDONESIA HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 118. JAPAN HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 119. JAPAN HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 120. JAPAN HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 121. JAPAN HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 122. JAPAN HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 123. JAPAN HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 124. JAPAN HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 125. MALAYSIA HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 126. MALAYSIA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 127. MALAYSIA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 128. MALAYSIA HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 129. MALAYSIA HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 130. MALAYSIA HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 131. MALAYSIA HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 132. PHILIPPINES HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 133. PHILIPPINES HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 134. PHILIPPINES HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 135. PHILIPPINES HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 136. PHILIPPINES HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 137. PHILIPPINES HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 138. PHILIPPINES HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 139. SINGAPORE HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 140. SINGAPORE HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 141. SINGAPORE HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 142. SINGAPORE HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 143. SINGAPORE HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 144. SINGAPORE HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 145. SINGAPORE HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 146. SOUTH KOREA HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 147. SOUTH KOREA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 148. SOUTH KOREA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 149. SOUTH KOREA HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 150. SOUTH KOREA HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 151. SOUTH KOREA HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 152. SOUTH KOREA HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 153. TAIWAN HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 154. TAIWAN HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 155. TAIWAN HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 156. TAIWAN HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 157. TAIWAN HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 158. TAIWAN HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 159. TAIWAN HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 160. THAILAND HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 161. THAILAND HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 162. THAILAND HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 163. THAILAND HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 164. THAILAND HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 165. THAILAND HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 166. THAILAND HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 167. VIETNAM HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 168. VIETNAM HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 169. VIETNAM HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 170. VIETNAM HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 171. VIETNAM HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 172. VIETNAM HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 173. VIETNAM HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA HEREDITARY TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 182. DENMARK HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 183. DENMARK HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 184. DENMARK HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 185. DENMARK HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 186. DENMARK HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 187. DENMARK HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 188. DENMARK HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 189. EGYPT HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 190. EGYPT HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 191. EGYPT HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 192. EGYPT HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 193. EGYPT HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 194. EGYPT HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 195. EGYPT HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 196. FINLAND HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 197. FINLAND HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 198. FINLAND HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 199. FINLAND HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 200. FINLAND HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 201. FINLAND HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 202. FINLAND HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 203. FRANCE HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 204. FRANCE HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 205. FRANCE HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 206. FRANCE HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 207. FRANCE HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 208. FRANCE HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 209. FRANCE HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 210. GERMANY HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 211. GERMANY HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 212. GERMANY HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 213. GERMANY HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 214. GERMANY HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 215. GERMANY HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 216. GERMANY HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 217. ISRAEL HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 218. ISRAEL HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 219. ISRAEL HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 220. ISRAEL HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 221. ISRAEL HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 222. ISRAEL HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 223. ISRAEL HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 224. ITALY HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 225. ITALY HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 226. ITALY HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 227. ITALY HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 228. ITALY HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 229. ITALY HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 230. ITALY HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 231. NETHERLANDS HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 232. NETHERLANDS HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 233. NETHERLANDS HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 234. NETHERLANDS HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 235. NETHERLANDS HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 236. NETHERLANDS HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 237. NETHERLANDS HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 238. NIGERIA HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 239. NIGERIA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 240. NIGERIA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 241. NIGERIA HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 242. NIGERIA HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 243. NIGERIA HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 244. NIGERIA HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 245. NORWAY HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 246. NORWAY HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 247. NORWAY HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 248. NORWAY HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 249. NORWAY HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 250. NORWAY HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 251. NORWAY HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 252. POLAND HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 253. POLAND HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 254. POLAND HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 255. POLAND HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 256. POLAND HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 257. POLAND HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 258. POLAND HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 259. QATAR HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 260. QATAR HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 261. QATAR HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 262. QATAR HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 263. QATAR HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 264. QATAR HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 265. QATAR HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 266. RUSSIA HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 267. RUSSIA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 268. RUSSIA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 269. RUSSIA HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 270. RUSSIA HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 271. RUSSIA HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 272. RUSSIA HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 273. SAUDI ARABIA HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 274. SAUDI ARABIA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 275. SAUDI ARABIA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 276. SAUDI ARABIA HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 277. SAUDI ARABIA HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 278. SAUDI ARABIA HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 279. SAUDI ARABIA HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 280. SOUTH AFRICA HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 281. SOUTH AFRICA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 282. SOUTH AFRICA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 283. SOUTH AFRICA HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 284. SOUTH AFRICA HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 285. SOUTH AFRICA HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 286. SOUTH AFRICA HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 287. SPAIN HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 288. SPAIN HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 289. SPAIN HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 290. SPAIN HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 291. SPAIN HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 292. SPAIN HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 293. SPAIN HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 294. SWEDEN HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 295. SWEDEN HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 296. SWEDEN HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 297. SWEDEN HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 298. SWEDEN HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 299. SWEDEN HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 300. SWEDEN HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 301. SWITZERLAND HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 302. SWITZERLAND HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 303. SWITZERLAND HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 304. SWITZERLAND HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 305. SWITZERLAND HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 306. SWITZERLAND HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 307. SWITZERLAND HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 308. TURKEY HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 309. TURKEY HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 310. TURKEY HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 311. TURKEY HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 312. TURKEY HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 313. TURKEY HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 314. TURKEY HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 315. UNITED ARAB EMIRATES HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 316. UNITED ARAB EMIRATES HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 317. UNITED ARAB EMIRATES HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 318. UNITED ARAB EMIRATES HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 319. UNITED ARAB EMIRATES HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 320. UNITED ARAB EMIRATES HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 321. UNITED ARAB EMIRATES HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 322. UNITED KINGDOM HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 323. UNITED KINGDOM HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 324. UNITED KINGDOM HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
TABLE 325. UNITED KINGDOM HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 326. UNITED KINGDOM HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 327. UNITED KINGDOM HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 328. UNITED KINGDOM HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 329. HEREDITARY TESTING MARKET, FPNV POSITIONING MATRIX, 2022
TABLE 330. HEREDITARY TESTING MARKET SHARE, BY KEY PLAYER, 2022
TABLE 331. HEREDITARY TESTING MARKET LICENSE & PRICING

Product Code: MRR-A339DAEFA86E

The Global Hereditary Testing Market is forecasted to grow significantly, with a projected USD 5,155.17 million in 2023 at a CAGR of 8.15% and expected to reach a staggering USD 8,934.75 million by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Hereditary Testing Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Hereditary Testing Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Disease Type, market is studied across Hereditary Cancer Testing, Hereditary Non-Cancer Testing, Newborn Genetic Screening, Non-Invasive Prenatal Testing & Carrier Screening Tests, and Preimplantation Genetic Diagnosis & Screening. The Hereditary Cancer Testing is further studied across Breast Cancer, Cervical Cancer, Colorectal Cancer, Lung Cancer, Melanoma, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Sarcoma, Stomach or Gastric Cancer, and Uterine Cancer. The Hereditary Non-Cancer Testing is further studied across Genetic Tests. The Genetic Tests is further studied across Cardiac Diseases and Rare Diseases. The Hereditary Cancer Testing is projected to witness significant market share during forecast period.

Based on Technology, market is studied across Biochemical, Cytogenetic, and Molecular Testing. The Molecular Testing is projected to witness significant market share during forecast period.

Based on Application, market is studied across Cancer Diagnosis, Cardiovascular Disease Diagnosis, and Genetic Disease Diagnosis. The Genetic Disease Diagnosis is projected to witness significant market share during forecast period.

Based on End-User, market is studied across Clinics and Hospitals. The Hospitals is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Hereditary Testing Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Hereditary Testing Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Hereditary Testing Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Hereditary Testing Market?

4. What is the competitive strategic window for opportunities in the Global Hereditary Testing Market?

5. What are the technology trends and regulatory frameworks in the Global Hereditary Testing Market?

6. What is the market share of the leading vendors in the Global Hereditary Testing Market?

7. What modes and strategic moves are considered suitable for entering the Global Hereditary Testing Market?

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Hereditary Testing Market, by Disease Type, 2022 vs 2030
4.3. Hereditary Testing Market, by Technology, 2022 vs 2030
4.4. Hereditary Testing Market, by Application, 2022 vs 2030
4.5. Hereditary Testing Market, by End-User, 2022 vs 2030
4.6. Hereditary Testing Market, by Region, 2022 vs 2030

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Exploration for changes or variants, in DNA to find root cause of potential disease
  - 5.1.1.2. Increased screening by pregnant women
  - 5.1.1.3. Rising R&D activities on advance Genome sequencing
- 5.1.2. Restraints
  - 5.1.2.1. Limited reimbursement policies
- 5.1.3. Opportunities
  - 5.1.3.1. Collaborative product development
  - 5.1.3.2. Attractive investment and amalgamation activity within value chain
- 5.1.4. Challenges
  - 5.1.4.1. Uncertain outcomes of the hereditary testing
5.2. Market Trends
5.3. Cumulative Impact of COVID-19
5.4. Cumulative Impact of Russia-Ukraine Conflict
5.5. Cumulative Impact of High Inflation
5.6. Porter's Five Forces Analysis
- 5.6.1. Threat of New Entrants
- 5.6.2. Threat of Substitutes
- 5.6.3. Bargaining Power of Customers
- 5.6.4. Bargaining Power of Suppliers
- 5.6.5. Industry Rivalry
5.7. Value Chain & Critical Path Analysis
5.8. Regulatory Framework
5.9. Client Customization

6. Hereditary Testing Market, by Disease Type

6.1. Introduction
6.2. Hereditary Cancer Testing
- 6.2.1. Breast Cancer
- 6.2.2. Cervical Cancer
- 6.2.3. Colorectal Cancer
- 6.2.4. Lung Cancer
- 6.2.5. Melanoma
- 6.2.6. Ovarian Cancer
- 6.2.7. Pancreatic Cancer
- 6.2.8. Prostate Cancer
- 6.2.9. Sarcoma
- 6.2.10. Stomach or Gastric Cancer
- 6.2.11. Uterine Cancer
6.3. Hereditary Non-Cancer Testing
- 6.3.1. Genetic Tests
  - 6.3.1.1. Cardiac Diseases
  - 6.3.1.2. Rare Diseases
6.4. Newborn Genetic Screening
6.5. Non-Invasive Prenatal Testing & Carrier Screening Tests
6.6. Preimplantation Genetic Diagnosis & Screening

7. Hereditary Testing Market, by Technology

7.1. Introduction
7.2. Biochemical
7.3. Cytogenetic
7.4. Molecular Testing

8. Hereditary Testing Market, by Application

8.1. Introduction
8.2. Cancer Diagnosis
8.3. Cardiovascular Disease Diagnosis
8.4. Genetic Disease Diagnosis

9. Hereditary Testing Market, by End-User

9.1. Introduction
9.2. Clinics
9.3. Hospitals

10. Americas Hereditary Testing Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Hereditary Testing Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa Hereditary Testing Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

遺伝学的検査市場：疾患タイプ、技術、用途、エンドユーザー別-2023-2030年の世界予測

Hereditary Testing Market by Disease Type, Technology, Application, End-User - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030

FPNVポジショニング・マトリックス

市場シェア分析

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

第6章 遺伝学的検査市場：疾患タイプ別

第7章 遺伝学的検査市場：技術別

第8章 遺伝学的検査市場：用途別

第9章 遺伝学的検査市場：エンドユーザー別

第10章 南北アメリカの遺伝学的検査市場

第11章 アジア太平洋地域の遺伝学的検査市場

第12章 欧州・中東・アフリカの遺伝学的検査市場

第13章 競合情勢

第14章 掲載企業一覧

第15章 付録